Company Overview and News

73
Comstock Resources Eyes Enduro Resource Assets, Places Bid

2018-06-11 zacks
Comstock Resources, Inc. (CRK - Free Report) , according to recent reports, has placed its bid for the Cotton Valley and Haynesville Shale assets of bankrupt Enduro Resource Partners LLC, an exploration and production company that is liquidating its properties. Founded in 2010 and backed by the private equity firm, Riverstone Holdings, Enduro Resource was hit by low oil price environment that shook the industry a few years back.
WFC WFCNP APC WFC.WS CRK WFC.PRL WFC.PRJ REVSF WFC.PRT WFC.PRR WFC.PRQ DK WFC.PRP WFC.PRO WFC.PRN HFC WFC.PRY WFC.PRX AEUA WFC.PRW WFC.PRV AP4

11
Industry Leader Yields 11%, Major Growth Starting In Q2 2018, Industry Turnaround

2018-05-17 seekingalpha
It reported record Q1 '18 earnings and closed on a major deal at the start of Q2 '18.
ETP.PRC ETP USAC REVSF AP4

4
OTC2018: CEO of 'Reset' Deepwater Operator Sees Better Days for GOM

2018-05-04 rigzone
The overall increase in crude oil prices notwithstanding, a “new attitude” toward U.S. Gulf of Mexico (GOM) operators among federal government regulators and the White House is helping deepwater oil and gas firms to better position themselves for growth in the short and long terms, the head of one of the largest GOM operators told Rigzone.
NBL REVSF AP4

4
CEO of 'Reset' Deepwater Operator Sees Better Days for Gulf of Mexico

2018-05-04 rigzone
The overall increase in crude oil prices notwithstanding, a “new attitude” toward U.S. Gulf of Mexico (GOM) operators among federal government regulators and the White House is helping deepwater oil and gas firms to better position themselves for growth in the short and long terms, the head of one of the largest GOM operators told Rigzone.
NBL REVSF AP4

4
Brian Alfaro Discusses the Strong M&A Interest in Permian Basin

2018-05-02 accesswire
SAN ANTONIO, TX / ACCESSWIRE / May 2, 2018 / Oil and gas (O&G) industry merger and acquisition (M&A) activities slowed for most of 2017, largely due to drillers focusing on consolidating their positions in a few core areas to contend with low oil prices by purchasing assets that allowed to connect pieces of land, drill more efficiently and improve cash flow. However, the money is starting to return this year with large energy companies playing a major role in deal making.
REVSF AP4

39
The AES Corporation - Potential 'Power' King?

2018-04-18 seekingalpha
Since 2012, AES has been under new management, expanded in countries where it could make a potential profit and exited the high-risk ones.
AES.PRC WM AES REVSF AP4

59
Blackstone Fund Buys Stake in Property Firm Rockpoint - Bloomberg

2018-03-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK GSC GS.PRICL TFG GS.PRB GS.PRA GSJ REVSF GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK AP4

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...